AbbVie’s eczema antibody shows statistically significant benefit in Phase 2 trial
read at Endpoints ↗Positive readoutNeutral
AbbVie presented Phase 2 results for its experimental eczema treatment, an anti‑IL‑13 antibody named Zumilokibart.
The study met its primary endpoints, demonstrating statistically significant improvements over placebo and suggesting the drug could be effective for atopic dermatitis.
Separately, BioMarin disclosed a workforce reduction, laying off 117 employees as part of a restructuring plan.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “AbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117”
read at Endpoints ↗81 words · retrieved 2h ago
comments(0)
5-min edit window · permanent after that